In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine [NSC-366140, PD115934] to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow

Journal of the National Cancer Institute

Volumn 86, Issue 4, 1994, Pages 273-280

  Parchment, Ralph E ^a   Volpe, Donna A ^a   Lorusso, Patricia M ^a   Erickson miller, Connie L ^a   Murphy, Martin J ^a   Grieshaber, Charles K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE;

ADOLESCENT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DOG; ERYTHROID PRECURSOR CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUTROPENIA; NONHUMAN; PROMYELOCYTE; SPECIES DIFFERENCE;

ACRIDINES; ANIMAL; ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW CELLS; CELLS, CULTURED; DOGS; ERYTHROID PROGENITOR CELLS; HUMAN; LEUKOCYTE COUNT; MICE; PYRAZOLES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028147434     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.4.273     Document Type: Article

References (16)

1. Du DL. Volpe DA, Murphy MJ Jr: Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells [published erratum appears in Int J Cell Cloning 7:395. 1989], Int J Cell Cloning 7:303-313, 1989
2. Volpe DA. Du DL. Pohl KP, et al: Utility of human bone marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays. Palhobiology 59:53-56. 1991
3. Parchment RE. Huang M, Erickson-Miller CL’ Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21:241-250, 1993
4. Du DL, Volpe DA. Grieshaber CK, et al: In vitro myelotoxicity of 2',3'-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hemalol 18:832-836. 1990
5. Du DL, Volpe DA, Grieshaber CK, et al: Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs 9:149-157. 1991
6. Du DL, Volpe DA, Grieshaber CK, et al: Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic cells in vitro. Cancer Res 50:4038-4043, 1990
7. Jackson RC, Sebolt JS, Shillis JL, et al: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8:39-47, 1990
8. Jackson RC: The problem of the quiescent cancer cell. Adv Enzyme Regul 29:27-46, 1989
9. Sebolt JS, Scavone SV. Pinter CD. et al: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47:4299-4304, 1987
10. Sebolt J, Havlick M, Hamelehle K, et al: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24:219-224, 1989
11. Cole SP: Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol 26:250-256, 1990
12. LoRusso P, Wozniak AJ, Polin L, et al: Antitumor efficacy of PD 115934 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900-4905. 1990
13. LoRusso PM, Foster BJ, Corbett TH, et al: Comparisons of results from preclinical studies and phase 1 trial with the pyrazoloacridine (PD 115934, NCS-366140) 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 17-20, 360a, 1992
14. Auber ML, Horwitz LJ, Blaauw A, et al: Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood 71166-172, 1988
15. Berg SL, Balis FM, McCully CL, et al: Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 51:5467-5470, 1991
16. Liao JTF, Collins WT, Boss SM, et al: Toxicological and pharmacokinetic evaluation of pyrazoloacridine (NSC-366140). Proc Am Assoc Cancer Res 31:abstr 26340, 1990